| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
α-Amyrin acetate targets multiple pathways involved in inflammation and cell proliferation. The compound inhibits cancer cell proliferation and induces apoptosis. It shows anti-inflammatory activity through modulation of inflammatory mediators. α-Amyrin acetate also exhibits antispasmodic and relaxant effects on smooth muscle. Its mechanism involves interaction with caspases, with reported Ki values of 0.8 nM for caspase-1. The compound's multi-target activity contributes to its diverse pharmacological effects.
|
|---|---|
| ln Vitro |
In vitro, α-amyrin acetate demonstrates anti-inflammatory, antispasmodic, and relaxant activities. The compound inhibits cancer cell proliferation and induces apoptosis in various cancer cell lines. Its anti-inflammatory effects are mediated through modulation of inflammatory cytokines and signaling pathways. The compound's antispasmodic activity is observed in smooth muscle preparations. α-Amyrin acetate also exhibits antifungal activity against various fungal pathogens.
|
| ln Vivo |
In vivo, α-amyrin acetate is orally active and exhibits antihyperglycemic, hepatoprotective, and anti-inflammatory effects. The compound reduces blood glucose levels and protects the liver from damage in animal models. Its anti-inflammatory activity has been demonstrated in various inflammatory disease models. α-Amyrin acetate's ability to inhibit cancer cell proliferation suggests potential anti-tumor efficacy in vivo. The compound's oral bioavailability supports its use in chronic studies.
|
| Enzyme Assay |
The in vitro enzyme assays for α-amyrin acetate involve measurement of caspase activity and inflammatory mediator levels. Caspase inhibition is assessed using fluorogenic substrates in cell-free systems. Anti-inflammatory activity is evaluated by measuring cytokine production in stimulated immune cells. Antioxidant activity is assessed using standard assays such as DPPH radical scavenging. The compound is tested at concentrations ranging from 0.1 to 100 µM, and IC₅₀ values are calculated from dose-response curves.
|
| Cell Assay |
In vitro cell-based experiments with α-amyrin acetate utilize various cell lines to evaluate anti-inflammatory, antiproliferative, and pro-apoptotic effects. Cells are cultured in appropriate media and treated with the compound at various concentrations. Cell viability is assessed using MTT assays. Apoptosis is evaluated by Annexin V/PI staining and caspase activity assays. Inflammatory cytokine production is measured by ELISA. Signaling pathway activation is assessed by Western blotting. All experiments include vehicle controls.
|
| Animal Protocol |
In vivo animal studies with α-amyrin acetate typically use rodent models of inflammation, diabetes, or cancer. The compound is administered orally at doses determined from preliminary studies. Inflammatory markers are measured in blood and tissue samples. Blood glucose levels are monitored in diabetic models. Tumor growth is measured in xenograft models. Histopathological examination of tissues is performed for hepatoprotective assessment. All procedures follow institutional animal care guidelines.
|
| References |
|
| Additional Infomation |
α-Amyrin acetate is a triterpenoid compound. It has been reported to exist in Leontodon filii, Morus cathayana, and other organisms with relevant data.
|
| Molecular Formula |
C32H52O2
|
|---|---|
| Molecular Weight |
468.75408
|
| Exact Mass |
468.396
|
| CAS # |
863-76-3
|
| PubChem CID |
92842
|
| Appearance |
White to off-white solid powder
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
508.0±50.0 °C at 760 mmHg
|
| Melting Point |
241ºC
|
| Flash Point |
258.0±17.7 °C
|
| Vapour Pressure |
0.0±1.3 mmHg at 25°C
|
| Index of Refraction |
1.528
|
| Source |
Originated from plants: other families
|
| LogP |
11.9
|
| tPSA |
26.3
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
34
|
| Complexity |
885
|
| Defined Atom Stereocenter Count |
10
|
| SMILES |
C[C@@]12CC[C@H]3C([C@H](CC[C@]3(C)[C@H]1CC=C1[C@@H]3[C@@H](C)[C@H](C)CC[C@@]3(CC[C@@]21C)C)OC(=O)C)(C)C
|
| InChi Key |
UDXDFWBZZQHDRO-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C32H52O2/c1-20-12-15-29(6)18-19-31(8)23(27(29)21(20)2)10-11-25-30(7)16-14-26(34-22(3)33)28(4,5)24(30)13-17-32(25,31)9/h10,20-21,24-27H,11-19H2,1-9H3
|
| Chemical Name |
(4,4,6a,6b,8a,11,12,14b-octamethyl-2,3,4a,5,6,7,8,9,10,11,12,12a,14,14a-tetradecahydro-1H-picen-3-yl) acetate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
Ethanol: ~1 mg/mL (~2.1 mM; with ultrasonication and warming by heating to 60°C)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 0.1 mg/mL (0.21 mM) (saturation unknown) in 10% EtOH + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of ethanol stock solution (1.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 0.1 mg/mL (0.21 mM) in 10% EtOH + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Suspended solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of EtOH stock solution (1.0 mg/mL) to 900 μL of corn oil and mix well.  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1333 mL | 10.6667 mL | 21.3333 mL | |
| 5 mM | 0.4267 mL | 2.1333 mL | 4.2667 mL | |
| 10 mM | 0.2133 mL | 1.0667 mL | 2.1333 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.